Off-label oral drugs (antidepressants, benzodiazepines, gabapentin, betahistine) for Tinnitus: What Does the Evidence Show?
Drugs & Pharmacology
Current evidence
No drug is approved for tinnitus anywhere — and the systematic reviews say none of the usual suspects works on the tinnitus itself.
Evidence strength: Weak (1/5) · Tier 5 — weak or unsupported · Evidence independence: Primarily independent.
Commonly prescribed medications used off-label: tricyclics/SSRIs, benzodiazepines, anticonvulsants (gabapentin), betahistine and others. There is no FDA- or EMA-approved drug for tinnitus.
Did tinnitus loudness improve?
None shown. No drug has shown a loudness effect in a confirmatory trial.
Did tinnitus distress improve?
Limited. Antidepressants can help comorbid depression/anxiety; Cochrane finds tricyclics no better than placebo for tinnitus severity; insufficient evidence for benzodiazepines; gabapentin ineffective; betahistine — 'absence of evidence'.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Half a century of trials without a single confirmatory win: 1/5 for tinnitus itself (comorbidity treatment is a separate, legitimate decision).
Has the result been independently replicated?
None yet.
What are the limitations?
- 2025 network meta-analysis: 78% of drug trials have methodological concerns; evidence low to very low
What should patients know about safety?
Safety evidence: Limited. Real side-effect burdens — benzodiazepine dependence, anticholinergic effects, sedation. Weigh against absent tinnitus benefit.
Is it available?
Regulatory status: No drug approved for tinnitus (all use off-label). AAO-HNSF 2014 recommends against routine antidepressants, anticonvulsants, anxiolytics and intratympanic drugs for tinnitus.
Availability: Prescription, off-label · Europe: Same (betahistine widely used for vertigo) · Cost (approx.): Generic pricing
What the studies found
Pharmacotherapy for subjective tinnitus: network meta-analysis of 60 RCTs
Li P, Che C, Wu Y, et al. · BMJ Open · 2025 · N=60 RCTs · Systematic review + network meta-analysis (>30 drug interventions)
No approved drug exists; 78% of included studies had methodological concerns; evidence quality low to very low. Tentative signals (antioxidants, GABA agonists) are hypothesis-generating only and conflict with Cochrane.
Betahistine for tinnitus (Cochrane Review)
Wegner I, et al. · Cochrane Database of Systematic Reviews · 2018 · N=5 studies, N≈305 · Systematic review
'Absence of evidence' of any effect on subjective idiopathic tinnitus vs placebo; well tolerated.
QUIET-1: AUT00063 (Kv3 modulator) Phase 2a — terminated for futility
Hall DA, Ray J, Watson J, et al. · Hearing Research · 2019 · N=91 · Randomized placebo-controlled Phase 2a
Terminated early for futility; TFI change ~1.6 points despite therapeutic-range drug exposure.
Cochrane: antidepressants for tinnitus (CD003853)
Baldo P, et al. · Cochrane Database of Systematic Reviews · 2012 · N=6 trials, 610 patients · Cochrane systematic review
Verbatim conclusion: 'There is as yet insufficient evidence to say that antidepressant drug therapy improves tinnitus.'
Distinct from treating comorbid depression, which can itself be worthwhile.
Neramexane for tinnitus: Phase 2 miss and unpublished Phase 3 program
Suckfüll M, et al. (Phase 2); Merz Pharmaceuticals (Phase 3 program) · BMC Ear, Nose and Throat Disorders (Phase 2) · 2011 · N=Phase 2: 431; Phase 3 program: NCT00739635 (411), NCT00772980 (400), NCT00955799 (455) · Phase 2 randomized placebo-controlled dose-ranging; three completed Phase 3 RCTs (results never published)
Phase 2: primary endpoint NOT met at any dose (50 mg p=0.098). The three Phase 3 trials completed ~2010–2011 and their efficacy results were NEVER PUBLISHED; the open-label extension was terminated (Dec 2011) and the program abandoned.
A cautionary publication-bias case: 'failure' cannot be verified from primary sources because no Phase 3 results exist in the literature — what is verifiable is completion, non-publication, termination of the extension, and abandonment.
Gabapentin for tinnitus: randomized double-blind trial (negative)
Piccirillo JF, et al. · Archives of Otolaryngology–Head & Neck Surgery · 2007 · N=115 analyzed (59 gabapentin / 56 placebo) · 8-week randomized double-blind placebo-controlled trial (900–3600 mg/day)
NEGATIVE: THI improved 11.3 vs 11.0 points — difference 0.03 [95% CI −5.5, 6.2], p=.91. 'Gabapentin is no more effective than placebo.'
Both arms improved equally — a clean demonstration of the placebo/natural-course response that uncontrolled tinnitus studies mistake for efficacy.
Cochrane: anticonvulsants for tinnitus (CD007960)
Hoekstra CE, et al. · Cochrane Database of Systematic Reviews · 2011 · N=7 RCTs, 453 patients · Cochrane systematic review
No evidence of a large positive effect; a small effect 'of doubtful clinical significance' was demonstrated, with significant risk of bias.
AAO-HNSF Clinical Practice Guideline: Tinnitus
Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)
RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.
Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.
Related clinical trials
Tracked trials are research in progress, not recommended treatments.
Related treatments
- SPI-1005 (ebselen) — The most advanced drug with a tinnitus-relevant claim — but its trials are in Meniere's disease, and the…
- TRTL-913 (GABA-A modulator) — A new $106M bet that a GABA-A drug can quiet tinnitus — Phase 2 starts soon; no human tinnitus data yet.
- Intratympanic drug injections — Injections through the eardrum keep failing their controlled tests — the placebo response is doing the work.
- Supplements (ginkgo, zinc, melatonin…) — Heavily marketed, repeatedly tested, consistently unsupported.
Evidence last reviewed: 2026-09-03 · Evidence included through: 2026-09-03 · Confidence: high. Open the interactive evidence profile.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.